{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,26]],"date-time":"2026-02-26T21:41:00Z","timestamp":1772142060839,"version":"3.50.1"},"reference-count":67,"publisher":"Wiley","issue":"11","license":[{"start":{"date-parts":[[2018,9,11]],"date-time":"2018-09-11T00:00:00Z","timestamp":1536624000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"funder":[{"name":"Iranian Evidence-Based Medicine Center of Excellence, Tabriz University of Medical Sciences, Iran"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Brit J Clinical Pharma"],"published-print":{"date-parts":[[2018,11]]},"abstract":"<jats:sec><jats:title>Aims<\/jats:title><jats:p>Lisinopril is an angiotensin\u2010converting\u2010enzyme inhibitor that is largely administered for off\u2010label uses. This study aims to provide a comprehensive review of off\u2010label uses of lisinopril to aid physicians to make evidence\u2010based decisions.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>The following bibliographic databases were searched from inception up to 30 March 2017: PubMed, EMBASE, the Cochrane Library, Cochrane Central Register of Controlled Trials, Scopus, Ovid and Proquest. This systematic review sought all randomized trials conducted on adult individuals comparing lisinopril on its off\u2010label uses with alternative drugs or placebos and reported direct or alternative clinical outcomes. Risk of bias assessment by using the Cochrane Collaboration risk\u2010of\u2010bias tool and quality evaluation took place.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Included studies demonstrated significant positive effects of lisinopril on proteinuric kidney disease; however, lisinopril caused a slight reduction of glomerular filtration rate (GFR) especially for patients with GFR\u00a0&lt;\u00a090\u00a0ml\u00a0min<jats:sup>\u20131<\/jats:sup>. Lisinopril offered better outcomes in comparison to other standard treatments of diabetic nephropathy. Other studies showed positive effects of lisinopril for migraine, prevention of diabetes, myocardial fibrosis, mitral valve regurgitation, cardiomyopathy in patients with Duchenne muscular dystrophy, oligospermia and infertility, and diabetic retinopathy. Conversely, the studies reported that lisinopril was ineffective for five other off\u2010label uses.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>The identified studies showed that lisinopril was highly effective for proteinuric kidney disease with a minor but inconsiderable decrease in GFR. Positive effects of lisinopril were demonstrated in seven other off\u2010label uses; however, lisinopril cannot be recommended as the first choice for these until further clinical trials confirm these positive effects.<\/jats:p><\/jats:sec>","DOI":"10.1111\/bcp.13705","type":"journal-article","created":{"date-parts":[[2018,7,4]],"date-time":"2018-07-04T01:55:07Z","timestamp":1530669307000},"page":"2502-2521","source":"Crossref","is-referenced-by-count":12,"title":["An evidence\u2010based systematic review of the off\u2010label uses of lisinopril"],"prefix":"10.1111","volume":"84","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6697-4372","authenticated-orcid":false,"given":"Seyyed\u2010Reza","family":"Sadat\u2010Ebrahimi","sequence":"first","affiliation":[{"name":"Research Center for Evidence\u2010Based Medicine, Health Management and Safety Promotion Research Institute Tabriz University of Medical Sciences  Tabriz Iran"},{"name":"Iranian EBM Center: A Joanna Briggs Institute Affiliated Group"},{"name":"Drug Applied Research Center Tabriz University of Medical Sciences  Tabriz Iran"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Neda","family":"Parnianfard","sequence":"additional","affiliation":[{"name":"Research Center for Evidence\u2010Based Medicine, Health Management and Safety Promotion Research Institute Tabriz University of Medical Sciences  Tabriz Iran"},{"name":"Iranian EBM Center: A Joanna Briggs Institute Affiliated Group"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nafiseh","family":"Vahed","sequence":"additional","affiliation":[{"name":"Research Center for Evidence\u2010Based Medicine, Health Management and Safety Promotion Research Institute Tabriz University of Medical Sciences  Tabriz Iran"},{"name":"Iranian EBM Center: A Joanna Briggs Institute Affiliated Group"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hossein","family":"Babaei","sequence":"additional","affiliation":[{"name":"Drug Applied Research Center Tabriz University of Medical Sciences  Tabriz Iran"},{"name":"Faculty of Pharmacology Tabriz University of Medical Sciences  Tabriz Iran"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Morteza","family":"Ghojazadeh","sequence":"additional","affiliation":[{"name":"Research Development &amp; Coordination Center, Faculty of Medicine Tabriz University of Medical Sciences  Tabriz Iran"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sydney","family":"Tang","sequence":"additional","affiliation":[{"name":"Division of Nephrology, Department of Medicine University of Hong Kong, Queen Mary Hospital  Hong Kong"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Amir","family":"Azarpazhooh","sequence":"additional","affiliation":[{"name":"Mount Sinai Hospital, Sinai Health System  Toronto Canada"},{"name":"Faculty of Dentistry University of Toronto  Toronto Canada"},{"name":"Clinical Epidemiology &amp; Health Care Research, Institute of Health Policy, Management and Evaluation, Faculty of Medicine University of Toronto  Toronto Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2018,9,11]]},"reference":[{"key":"e_1_2_10_2_1","unstructured":"Frankel D.Office of Technology Assessment. Drug labeling in developing countries. OTA\u2010H\u2010464 Washington 1993."},{"key":"e_1_2_10_3_1","doi-asserted-by":"crossref","unstructured":"WittichCM BurkleCM LanierWL editors.Ten common questions (and their answers) about off\u2010label drug use. Mayo Clin Proc;2012: Elsevier.","DOI":"10.1016\/j.mayocp.2012.04.017"},{"key":"e_1_2_10_4_1","doi-asserted-by":"publisher","DOI":"10.1001\/archinternmed.2012.340"},{"key":"e_1_2_10_5_1","doi-asserted-by":"publisher","DOI":"10.1001\/archinte.166.9.1021"},{"key":"e_1_2_10_6_1","doi-asserted-by":"publisher","DOI":"10.1001\/archpedi.161.3.282"},{"key":"e_1_2_10_7_1","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2011-2744"},{"key":"e_1_2_10_8_1","unstructured":"DworkinRH O'ConnorAB AudetteJ BaronR GourlayGK Haanp\u00e4\u00e4ML et al. editors.Recommendations for the pharmacological management of neuropathic pain: an overview and literature update. Mayo Clin Proc;2010: Elsevier."},{"key":"e_1_2_10_9_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMp0802107"},{"key":"e_1_2_10_10_1","doi-asserted-by":"publisher","DOI":"10.1592\/phco.28.12.1443"},{"key":"e_1_2_10_11_1","unstructured":"Approval letter for Prinivil: Food and Drug Administration of USA. Available athttp:\/\/www.accessdata.fda.gov\/drugsatfda\u2013docs\/appletter\/2008\/019558s051 20s052ltr.pdf(last accessed 20 December 2016)."},{"key":"e_1_2_10_12_1","unstructured":"Approval letter for Zestril: Food and Drug Administration of USA. Available athttp:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/pre96\/19777-S002_ZESTRIL_APPROV.PDF(last accessed 20 December 2016)."},{"key":"e_1_2_10_13_1","unstructured":"Prescribing information of Zestoretic: AstraZeneca pharmaceuticals LP Wilmington. DE 19850. Available atwww.accessdata.fda.gov\/drugsatfda_docs\/label\/2012\/019888s051lbl.pdf(updated May 2012; last accessed 20 December 2016)."},{"key":"e_1_2_10_14_1","unstructured":"Approval letter for Qbrelis: Food and Drug Administration of USA. Available atwww.accessdata.fda.gov\/drugsatfda_docs\/nda\/2016\/208401Orig1s000Approv.pdf(last accessed 2 December 2016)."},{"key":"e_1_2_10_15_1","doi-asserted-by":"publisher","DOI":"10.1053\/j.ajkd.2007.04.013"},{"key":"e_1_2_10_16_1","first-page":"33","article-title":"Cochrane handbook for systematic reviews of interventions 5.1. 0","author":"Higgins JP","year":"2011","journal-title":"The Cochrane Collaboration"},{"key":"e_1_2_10_17_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0895-7061(98)00129-0"},{"key":"e_1_2_10_18_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1523-1755.2002.00536.x"},{"key":"e_1_2_10_19_1","doi-asserted-by":"publisher","DOI":"10.1097\/HJH.0b013e32830508aa"},{"key":"e_1_2_10_20_1","doi-asserted-by":"publisher","DOI":"10.1038\/clpt.1994.143"},{"key":"e_1_2_10_21_1","doi-asserted-by":"publisher","DOI":"10.1053\/j.ajkd.2012.07.011"},{"key":"e_1_2_10_22_1","doi-asserted-by":"publisher","DOI":"10.2337\/diacare.21.1.104"},{"key":"e_1_2_10_23_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0272-6386(97)90464-9"},{"key":"e_1_2_10_24_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.321.7274.1440"},{"key":"e_1_2_10_25_1","doi-asserted-by":"publisher","DOI":"10.2337\/diab.46.7.1182"},{"key":"e_1_2_10_26_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2796.2001.00821.x"},{"key":"e_1_2_10_27_1","doi-asserted-by":"crossref","first-page":"481","DOI":"10.2337\/diab.46.3.481","article-title":"Differences between Nisoldipine and Lisinopril on glomerular filtration rates and albuminuria in hypertensive IDDM patients with diabetic nephropathy during the first year of treatment","volume":"46","author":"Rossing P","year":"1997","journal-title":"Diabetes"},{"key":"e_1_2_10_28_1","doi-asserted-by":"publisher","DOI":"10.2337\/diacare.23.12.1725"},{"key":"e_1_2_10_29_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(96)10244-0"},{"key":"e_1_2_10_30_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00467-013-2494-8"},{"key":"e_1_2_10_31_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1071-9164(05)80004-1"},{"key":"e_1_2_10_32_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2009.08.020"},{"key":"e_1_2_10_33_1","article-title":"A randomized, double\u2010blind trial of Lisinopril and Losartan for the treatment of cardiomyopathy in Duchenne muscular dystrophy","volume":"5","author":"Allen HD","year":"2013","journal-title":"PLoS Curr"},{"key":"e_1_2_10_34_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jash.2016.10.010"},{"key":"e_1_2_10_35_1","doi-asserted-by":"publisher","DOI":"10.1161\/01.CIR.102.12.1388"},{"key":"e_1_2_10_36_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0828-282X(06)70251-3"},{"key":"e_1_2_10_37_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1755-3768.2009.01847.x"},{"key":"e_1_2_10_38_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(97)06209-0"},{"key":"e_1_2_10_39_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2125.1998.00811.x"},{"key":"e_1_2_10_40_1","first-page":"37","article-title":"Major outcomes in high\u2010risk hypertensive patients randomized to angiotensin\u2010converting enzyme inhibitor or calcium channel blocker vs. diuretic. The antihypertensive and lipid\u2010lowering treatment to prevent heart attack trial (ALLHAT)","volume":"12","author":"The ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group","year":"2002","journal-title":"ACC Curr J Rev"},{"key":"e_1_2_10_41_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajo.2005.11.056"},{"key":"e_1_2_10_42_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.322.7277.19"},{"key":"e_1_2_10_43_1","doi-asserted-by":"publisher","DOI":"10.1038\/clpt.2011.265"},{"key":"e_1_2_10_44_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jamda.2015.05.009"},{"key":"e_1_2_10_45_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00125-011-2398-8"},{"key":"e_1_2_10_46_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.38237.585000.7C"},{"key":"e_1_2_10_47_1","doi-asserted-by":"publisher","DOI":"10.1001\/archinte.160.5.685"},{"key":"e_1_2_10_48_1","unstructured":"American Diabetes Association.Standards of medical Care in Diabetes Guidline.2017."},{"key":"e_1_2_10_49_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1464-5491.2003.00969.x"},{"key":"e_1_2_10_50_1","doi-asserted-by":"publisher","DOI":"10.1258\/ebm.2011.010375"},{"key":"e_1_2_10_51_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-8587(14)70256-6"},{"key":"e_1_2_10_52_1","doi-asserted-by":"publisher","DOI":"10.2478\/v10039-011-0023-1"},{"key":"e_1_2_10_53_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10557-011-6346-0"},{"key":"e_1_2_10_54_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11940-016-0397-2"},{"key":"e_1_2_10_55_1","first-page":"91","article-title":"The role of renin blockers in the prevention of diabetes","volume":"28","author":"Alkhenizan AH","year":"2007","journal-title":"Saudi Med J"},{"key":"e_1_2_10_56_1","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1136\/jim-2015-000035.1","article-title":"Southern regional meeting, New Orleans, February 18\u201020, 2016","volume":"64","year":"2016","journal-title":"J Invest Med"},{"key":"e_1_2_10_57_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijcard.2016.02.089"},{"key":"e_1_2_10_58_1","first-page":"357","article-title":"The influence of chronic treatment with betablockade and angiotensin converting enzyme inhibition on the peripheral blood flow in hypertensive patients with and without concomitant intermittent claudication. A comparative cross\u2010over trial","volume":"23","author":"Van de Ven L","year":"1993","journal-title":"VASA Zeitschrift fur Gefasskrankheiten"},{"key":"e_1_2_10_59_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.thj.6200571"},{"key":"e_1_2_10_60_1","doi-asserted-by":"publisher","DOI":"10.1002\/ccd.1810230407"},{"key":"e_1_2_10_61_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(06)69250-7"},{"key":"e_1_2_10_62_1","doi-asserted-by":"crossref","first-page":"e0166362","DOI":"10.1371\/journal.pone.0166362","article-title":"Angiotensin converting\u2010enzyme inhibitors, angiotensin receptor blockers, and calcium channel blockers are associated with prolonged vascular access patency in uremic patients undergoing hemodialysis","volume":"11","author":"Chen FA","year":"2017","journal-title":"PLoS One"},{"key":"e_1_2_10_63_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0272-6386(12)80616-0"},{"key":"e_1_2_10_64_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1468-2982.2003.00627.x"},{"key":"e_1_2_10_65_1","doi-asserted-by":"publisher","DOI":"10.1159\/000046231"},{"key":"e_1_2_10_66_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0015-0282(01)03210-1"},{"key":"e_1_2_10_67_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1464-5491.1995.tb00482.x"},{"key":"e_1_2_10_68_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11357-011-9360-z"}],"container-title":["British Journal of Clinical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fbcp.13705","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/bcp.13705","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/bcp.13705","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/bpspubs.onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/bcp.13705","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,10]],"date-time":"2023-09-10T12:31:47Z","timestamp":1694349107000},"score":1,"resource":{"primary":{"URL":"https:\/\/bpspubs.onlinelibrary.wiley.com\/doi\/10.1111\/bcp.13705"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,9,11]]},"references-count":67,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2018,11]]}},"alternative-id":["10.1111\/bcp.13705"],"URL":"https:\/\/doi.org\/10.1111\/bcp.13705","archive":["Portico"],"relation":{},"ISSN":["0306-5251","1365-2125"],"issn-type":[{"value":"0306-5251","type":"print"},{"value":"1365-2125","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,9,11]]}}}